Cationic Poly(Amino Acid) Vaccine Adjuvant for Promoting Both Cell-Mediated and Humoral Immunity Against Influenza Virus

Jong Woo Lim; Woonsung Na; Hyun Ouk Kim; Minjoo Yeom; Geunseon Park; Aram Kang; Haejin Chun; Chaewon Park; Seungseok Oh; Van Phan Le; Hyoung Hwa Jeong; Daesub Song; Seungjoo Haam

doi:10.1002/adhm.201800953

Cationic Poly(Amino Acid) Vaccine Adjuvant for Promoting Both Cell-Mediated and Humoral Immunity Against Influenza Virus

Jong Woo Lim, Woonsung Na, Hyun Ouk Kim, Minjoo Yeom, Geunseon Park, Aram Kang, Haejin Chun, Chaewon Park, Seungseok Oh, Van Phan Le, Hyoung Hwa Jeong, Daesub Song, Seungjoo Haam

Department of Chemical and Biomolecular Engineering

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Powerful adjuvants to augment vaccine efficacy with a less immunogenic vaccine system are in great demand. In this study, a novel squalene-based cationic poly(amino acid) adjuvant (CASq) that elicits both cellular (Th1) and humoral (Th2) immune responses is developed. CASq is demonstrated to promote cellular uptake of viral antigen and stimulate macrophages, leading to active production of interleukin-12. Furthermore, co-administration of inactivated pdm H1N1 vaccine with CASq significantly increases the generation of antigen-specific antibodies and T cell immune responses in mice, as well as resulting in complete prevention of disease symptoms and protection against lethal infection.

Original language	English
Article number	1800953
Journal	Advanced Healthcare Materials
Volume	8
Issue number	2
DOIs	https://doi.org/10.1002/adhm.201800953
Publication status	Published - 2019 Jan 24

Bibliographical note

Funding Information:
J.-W.L. and W.N. contributed equally to this work. This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT (NRF-2018M3A9H4056340).

Publisher Copyright:
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All Science Journal Classification (ASJC) codes

Biomaterials
Biomedical Engineering
Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/adhm.201800953

Cite this

@article{fffe8df11fe3458f892889908c165f6c,

title = "Cationic Poly(Amino Acid) Vaccine Adjuvant for Promoting Both Cell-Mediated and Humoral Immunity Against Influenza Virus",

abstract = "Powerful adjuvants to augment vaccine efficacy with a less immunogenic vaccine system are in great demand. In this study, a novel squalene-based cationic poly(amino acid) adjuvant (CASq) that elicits both cellular (Th1) and humoral (Th2) immune responses is developed. CASq is demonstrated to promote cellular uptake of viral antigen and stimulate macrophages, leading to active production of interleukin-12. Furthermore, co-administration of inactivated pdm H1N1 vaccine with CASq significantly increases the generation of antigen-specific antibodies and T cell immune responses in mice, as well as resulting in complete prevention of disease symptoms and protection against lethal infection.",

author = "Lim, {Jong Woo} and Woonsung Na and Kim, {Hyun Ouk} and Minjoo Yeom and Geunseon Park and Aram Kang and Haejin Chun and Chaewon Park and Seungseok Oh and Le, {Van Phan} and Jeong, {Hyoung Hwa} and Daesub Song and Seungjoo Haam",

note = "Funding Information: J.-W.L. and W.N. contributed equally to this work. This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT (NRF-2018M3A9H4056340). Publisher Copyright: {\textcopyright} 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim",

year = "2019",

month = jan,

day = "24",

doi = "10.1002/adhm.201800953",

language = "English",

volume = "8",

journal = "Advanced healthcare materials",

issn = "2192-2640",

publisher = "John Wiley and Sons Ltd",

number = "2",

}

TY - JOUR

T1 - Cationic Poly(Amino Acid) Vaccine Adjuvant for Promoting Both Cell-Mediated and Humoral Immunity Against Influenza Virus

AU - Lim, Jong Woo

AU - Na, Woonsung

AU - Kim, Hyun Ouk

AU - Yeom, Minjoo

AU - Park, Geunseon

AU - Kang, Aram

AU - Chun, Haejin

AU - Park, Chaewon

AU - Oh, Seungseok

AU - Le, Van Phan

AU - Jeong, Hyoung Hwa

AU - Song, Daesub

AU - Haam, Seungjoo

N1 - Funding Information: J.-W.L. and W.N. contributed equally to this work. This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT (NRF-2018M3A9H4056340). Publisher Copyright: © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

PY - 2019/1/24

Y1 - 2019/1/24

N2 - Powerful adjuvants to augment vaccine efficacy with a less immunogenic vaccine system are in great demand. In this study, a novel squalene-based cationic poly(amino acid) adjuvant (CASq) that elicits both cellular (Th1) and humoral (Th2) immune responses is developed. CASq is demonstrated to promote cellular uptake of viral antigen and stimulate macrophages, leading to active production of interleukin-12. Furthermore, co-administration of inactivated pdm H1N1 vaccine with CASq significantly increases the generation of antigen-specific antibodies and T cell immune responses in mice, as well as resulting in complete prevention of disease symptoms and protection against lethal infection.

AB - Powerful adjuvants to augment vaccine efficacy with a less immunogenic vaccine system are in great demand. In this study, a novel squalene-based cationic poly(amino acid) adjuvant (CASq) that elicits both cellular (Th1) and humoral (Th2) immune responses is developed. CASq is demonstrated to promote cellular uptake of viral antigen and stimulate macrophages, leading to active production of interleukin-12. Furthermore, co-administration of inactivated pdm H1N1 vaccine with CASq significantly increases the generation of antigen-specific antibodies and T cell immune responses in mice, as well as resulting in complete prevention of disease symptoms and protection against lethal infection.

UR - http://www.scopus.com/inward/record.url?scp=85058442959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058442959&partnerID=8YFLogxK

U2 - 10.1002/adhm.201800953

DO - 10.1002/adhm.201800953

M3 - Article

C2 - 30549426

AN - SCOPUS:85058442959

VL - 8

JO - Advanced healthcare materials

JF - Advanced healthcare materials

SN - 2192-2640

IS - 2

M1 - 1800953

ER -

Cationic Poly(Amino Acid) Vaccine Adjuvant for Promoting Both Cell-Mediated and Humoral Immunity Against Influenza Virus

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this